American Academy of Allergy, Asthma, and Immunology Annual Meeting (AAAAI 2024)

Treatment with dupilumab helps normalize the expression of genes dysregulated in children with active eosinophilic esophagitis (EoE), according to a study.

Mepolizumab proves beneficial to adults with chronic rhinosinusitis with nasal polyps treated in routine clinical practice, especially in terms of reducing oral corticosteroid (OCS) and surgical burden, according to a study. This supports clinical data from the pivotal phase III SYNAPSE study.

A substantial number of plasma samples from immunocompetent people who had SARS-CoV-2 infection more than a year ago appears to contain detectable viral antigens.

Patients who are suffering from hereditary angioedema (HAE) may find comfort by using drugs that have been recently shown to ease HAE attacks. Treatment with either garadacimab or berotralstat results in reduced attack rates, according to studies presented at AAAAI 2024.

Once-daily application of tapinarof cream 1% significantly improves the Eczema Area Severity Index (EASI) score in patients with atopic dermatitis (AD), regardless of their disease severity or age, according to the pivotal phase III ADORING 1 and 2 trials presented at AAAAI 2024.

Ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, appears to be effective for mild-to-moderate atopic dermatitis (AD) in children aged 2–11 years, according to the TRuE-AD3 trial presented at AAAAI 2024.

In the phase III KONFIDENT trial, oral sebetralstat provides rapid symptom relief, cuts treatment burden, and facilitates early treatment in individuals with hereditary angioedema (HAE) attacks.